Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InspireMDSTU:II2 -1.38%47 3-Year EPS without NRI Growth Rate is 31.40% as of Jun. 2026, which is 55% below its 10-year median of 70.40. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 662 Medical Devices & Instruments companies, InspireMD ranks better than 78.7% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 31.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 35.00% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 76.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of InspireMD was 94.40% per year. The lowest was 27.90% per year. And the median was 70.40% per year.
InspireMD (STU:II2) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
InspireMD 3-Year EPS without NRI Growth Rate Related Terms
STU:II2 vs SNWV, PAVM, ELUT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, InspireMD's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where InspireMD's 3-Year EPS without NRI Growth Rate falls into.
InspireMD 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 31.40% mean?
InspireMD (STU:II2) has a 3-Year EPS without NRI Growth Rate of 31.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for InspireMD and its competitors. This is 55% below median its historical median of 70.40. Over the past decade, InspireMD's 3-Year EPS without NRI Growth Rate has ranged from 27.90 to 94.40. According to the industry distribution chart, InspireMD ranks #141 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 21.3%.
Is InspireMD's 3-Year EPS without NRI Growth Rate too high?
InspireMD's current 3-Year EPS without NRI Growth Rate of 31.40% is 55% below median its 10-year median of 70.40. Over the past 10 years, this metric has ranged from a low of 27.90 to a high of 94.40. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 7.90. InspireMD's value of 31.40% is 297.5% above this industry median. Based on the distribution chart, InspireMD ranks #141 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's 3-Year EPS without NRI Growth Rate compare to SNWV and PAVM?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #141 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places InspireMD in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 7.90. InspireMD's value of 31.40% is 297.5% above this benchmark. Historically, InspireMD's own 3-Year EPS without NRI Growth Rate has ranged from 27.90 to 94.40 over the past decade. While the company's 10-year median is 70.40 vs. the industry median of 7.90, InspireMD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 7.90, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InspireMD's current 3-Year EPS without NRI Growth Rate of 31.40% is 297.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for InspireMD and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current 3-Year EPS without NRI Growth Rate is 31.40%, which is 55% below median its own 10-year median of 70.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.37, compared to a current price of €0.72 — trading 47.8% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 31.40%, which is 55% below median its 10-year median of 70.40 and 297.5% above the Medical Devices & Instruments industry median of 7.90. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For InspireMD (STU:II2), the current 3-Year EPS without NRI Growth Rate is 31.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.72 is trading 47.8% below its estimated GF Value™ of €1.37.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
3-Year EPS without NRI Growth Rate: 31.40% (55% below median its 10-year median of 70.40)
GF Value™: €1.37 vs. price of €0.72 (47.8% below fair value)
Industry Position: 297.5% above the Medical Devices & Instruments median (#141 of 662)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score
Get the complete analysis for STU:II2
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 
